On March 6, 2020, COVID-19 vaccine mRNA- 1273, which was jointly developed by Moderna and the Institute of Allergy and Infectious Diseases of the National Institutes of Health, began the first phase of clinical trial. It took only 63 days from sequence selection to the first human trial. The experiment was conducted at Kaiser Medical Group Washington Institute of Health in Seattle, and 45 healthy volunteers aged 18 to 55 will participate in the experiment.
This experiment will provide important data about the safety and immunogenicity of mRNA- 1273.
On March 23, 2020, Moderna disclosed the research and development progress of COVID-19 vaccine mRNA- 1273 in its report to the US Securities and Exchange Commission: Although the commercially available vaccine may not be available for at least 12 to 18 months, it is possible to provide vaccines for some groups including medical personnel in the autumn of 2020 for emergency use.
Moderna explained that the premise of "providing vaccine in an emergency" is based on the permission of the management organization and will be supported by the clinical data of mRNA- 1273. The company also revealed that if the mRNA- 1273 vaccine is proved to be safe and has expected benefits, the company will expand its production capacity and produce millions of doses of vaccine every month to ensure that the vaccine is widely supplied as soon as possible.
Refer to the above information: Baidu Encyclopedia -Moderna